UBS Group
LIMNW

UBS Group’s Liminatus Pharma Warrants LIMNW Stock Holding History

UBS Group’s Portfolio LIMNW Stock Details LIMNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$338 Hold
4,507
– – ﹤0.01% 9913
2026
Q1 		$180 Buy
4,507
+295
+7% +$19 ﹤0.01% 10048
2025
Q4 		$147 Buy
4,212
+3,922
+1,352% +$396 ﹤0.01% 10146
2025
Q3 		$43 Sell
290
-1,730
-86% -$338 ﹤0.01% 10041
2025
Q2 		$485 Buy
+2,020
New +$397 ﹤0.01% 9814

Other funds holding LIMNW

AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
SCM
Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
ACA
Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return

UBS Group's LIMNW Position: Q2 2026 in Review

UBS Group held its Liminatus Pharma Warrants (LIMNW) position steady in Q2 2026 at 4,507 shares worth $338. The position accounts for ﹤0.01% of the portfolio, ranked #9913.

UBS Group first reported a position in LIMNW in Q2 2025 and has held it in 5 quarters since. The position peaked at $485 in Q2 2025. 22 funds tracked by Wall St. Rank hold LIMNW as of Q2 2026.

  • UBS Group held 4,507 shares of Liminatus Pharma Warrants worth $338 as of Q2 2026.
  • UBS Group left its Liminatus Pharma Warrants share count unchanged in Q2 2026.
  • Liminatus Pharma Warrants made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9913 holding.
  • UBS Group first reported a position in Liminatus Pharma Warrants in Q2 2025 and has held it in 5 quarters since.
  • UBS Group's Liminatus Pharma Warrants position peaked at $485 in Q2 2025.
  • 22 funds tracked by Wall St. Rank held Liminatus Pharma Warrants as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.